UCM Stock Overview
Designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Uscom Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.032 |
| 52 Week High | AU$0.034 |
| 52 Week Low | AU$0.012 |
| Beta | -1.66 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -72.17% |
| 5 Year Change | -75.38% |
| Change since IPO | -84.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| UCM | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 39.1% | 0.6% | 1.4% |
| 1Y | n/a | 15.3% | 17.7% |
Return vs Industry: Insufficient data to determine how UCM performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how UCM performed against the Australian Market.
Price Volatility
| UCM volatility | |
|---|---|
| UCM Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: UCM's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine UCM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Rob Phillips | www.uscom.com.au |
Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma.
Uscom Limited Fundamentals Summary
| UCM fundamental statistics | |
|---|---|
| Market cap | AU$8.27m |
| Earnings (TTM) | -AU$2.07m |
| Revenue (TTM) | AU$3.73m |
2.1x
P/S Ratio-3.7x
P/E RatioIs UCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UCM income statement (TTM) | |
|---|---|
| Revenue | AU$3.73m |
| Cost of Revenue | AU$611.15k |
| Gross Profit | AU$3.12m |
| Other Expenses | AU$5.19m |
| Earnings | -AU$2.07m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 83.60% |
| Net Profit Margin | -55.67% |
| Debt/Equity Ratio | 0% |
How did UCM perform over the long term?
See historical performance and comparison